Home

About Us

Executive team

Corporate Structure

Brand

Our History

Our Culture

News Releases

Business

R&D

Manufacturing

Distribution

Career

Talent concept

Cultivation of talents

Social Responsibility

Responsibility Management

CSR Report

CSR News

Investor Relations

Corporate Governance

Announcements

Financial Reports

Company Presentations

Stock Price

Analyst Coverage

Investor Relations Contacts

CN EN

News Releases

Home>News Releases

Headlines

NIP Pharm’s Innovative Drug NIP142 Approved for Clinical Trials for NSCLC

　　Recently, National Institute of Pharmaceutical R&D Co., Ltd. (NIP Pharm), a subsidiary of CR Pharmaceutical Group, received the Notice of Drug Clinical Trial Approval from the ...

　　Recently, National Institute of Pharmaceutical R&D Co., Ltd. (NIP Pharm), a subsidiary of CR Pharmaceutical Group, received the Noti...

Detailed>>

Detailed +

2021.10

2021.10.09

NIP Pharm’s Innovative Drug NIP142 Approved for Clinical Trials for NSCLC

　　Recently, National Institute of Pharmaceutical R&D Co., Ltd. (NIP Pharm), a subsidiary of CR Pharmaceutical Group, received the Noti...

2021.10

2021.10.08

A Delegation Led by Zhang Boli Visiting CR Sanjiu

　　On October 7, a delegation led by Zhang Boli, an academician with the Chinese Academy of Engineering and recipient of the national h...

2021.09

2021.09.17

Remaining Committed to Charity - The CR Healthy Village Program Keeping up the Good Work

Remaining Committed to Charity - The CR Healthy Village Program Keeping...

　　The meeting for wrapping up the CR Healthy Village Program with the theme of “Boosting Primary-Level Medical Services and Supportin...

2021.08

2021.08.04

CR Double-Crane’s Sodium Valproate Tablets Fluconazole and Sodium Chloride Injection Passing Consistency Evaluation of Generic Drugs

CR Double-Crane’s Sodium Valproate Tablets Fluconazole and Sodium Chlo...

　　On August 4, CR Double-Crane issued an announcement that the Sodium Valproate Tablets produced by Hunan Xiangzhong Pharmaceutical Co...

2021.07

2021.07.21

CR Double-Crane and NOVITA signed an exclusive license agreement on the development, production and commercialization of NP-G2-044 Fascin inhibitor in Greater China.

CR Double-Crane and NOVITA signed an exclusive license agreement on the...

　　On July 21, CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane), a subsidiary of China Resources P...

2021.07

2021.07.20

CR Pharmaceutical proposed to acquire 10.0% stake in Immunotech Biopharm

　　On 20 July, Beijing Pharmaceutical Investment and Management (BVI) Limited, a wholly-owned subsidiary of the Company and as a purcha...

2021.07

2021.07.12

CR Biopharmaceutical and Biocytogen reach a comprehensive strategic cooperation for the development of multiple target antibody drugs

CR Biopharmaceutical and Biocytogen reach a comprehensive strategic coo...

　　On July 12, China Resources Biopharmaceutical Co., Ltd. (hereafter referred to as CR Biopharmaceutical) and Biocytogen Pharmaceutica...